Gitnux/Report 2026

Pain Management Industry Statistics

The global pain management market is estimated at $80.93B in 2026, explore the figures behind growth, company profiles, and key trends.
25Statistics
27Sources
6Sections
1Visuals
15mRead
November 22, 2026Updated
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 37 days

01 Industry overview

The pain management industry at a glance

The global pain management market is estimated at $80.93 billion in 2026, with growth supported by chronic pain prevalence, non-opioid innovation and expanding interventional services.

$80.93B[11]
Global market size, 2026
4.7%[11]
Forecast CAGR, 2026
24.3%[9]
U.S. adults with chronic pain, 2023
$58.3M[12]
JOURNAVX revenue, Q3 2026
Market size
The global pain management market is expected to reach $80.93 billion in 2026, up from $77.3 billion in 2025. The U.S. pain management services market was estimated at $44.5 billion in 2024.[11][2]
Forecast & CAGR
The global market is forecast to grow at a 4.7% CAGR from 2026 onward in the cited 2026 market forecast. U.S. pain management services are projected to increase from $44.5 billion in 2024 to $53.6 billion in 2030, a 3.1% CAGR.[11][2]
Market share & regions
North America accounted for 38% of the global pain management market in 2025, making it the largest regional market. The cited forecast covers North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.[13]
Segmentation
The global pain management drugs market was valued at $74.02 billion in 2025. Major drug-class segments include NSAIDs, opioids, anesthetics, antidepressants and anticonvulsants, while common indication segments include acute, neuropathic and musculoskeletal pain.[14]
Trends, drivers & challenges
Demand is supported by the high prevalence of chronic pain, with 24.3% of U.S. adults reporting chronic pain and 8.5% reporting high-impact chronic pain in 2023. The industry is also shifting toward non-opioid and minimally invasive options, while opioid misuse, addiction and overdose risks remain major constraints.[9][15]
Consumer behavior & competition
Chronic pain affected 24.3% of U.S. adults in 2023, creating a large treatment population across pharmaceutical, procedural and device-based care. Competition is increasingly focused on non-opioid therapies; in the third quarter of 2026, Vertex reported more than 750,000 JOURNAVX prescriptions and $58.3 million in revenue.[9][12]
M&A
Eli Lilly agreed in May 2025 to acquire SiteOne Therapeutics, adding the Phase 2-ready STC-004 Nav1.8 pain candidate; shareholders could receive up to $1.0 billion in cash. In March 2026, Resolve Pain Solutions acquired Southcoast Spine and Pain, expanding its interventional pain platform into South Carolina and six southern U.S. states.[16][17]
Regulation
The FDA approved Journavx (suzetrigine) in January 2025 as the first drug in a new class of non-opioid analgesics for moderate-to-severe acute pain in adults. In July 2025, the FDA also required safety-labeling changes for all opioid pain medicines to emphasize risks associated with long-term use, including misuse, addiction and overdose.[15]
Latest news
In the third quarter of 2026, Vertex reported $58.3 million in JOURNAVX revenue, up from $19.6 million in the third quarter of 2025, and more than 750,000 prescriptions filled. As of August 2026, Vertex said JOURNAVX had become the most prescribed branded oral pain medicine in the United States.[12]

02 Ranking

Top 10 Companies in the Pain Management Industry

The leading companies in the pain management industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Boston Scientific stands out for neuromodulation-focused chronic pain care because its Neuromodulation segment generated $1.199bn in 2025 including its Pain franchise, while Eli Lilly and Company focuses on migraine medicines since it is identified among the major companies operating in global pain management markets.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in neuromodulation devices

    Boston Scientific

    US

    Ranked #1 · 9.3 · Neuromodulation devices

    Why we picked it: Its Neuromodulation segment includes its Pain franchise, generating $1.199bn in 2025.

  2. Leader in migraine medicines

    Eli Lilly and Company

    US

    Ranked #2 · 9.1 · Migraine medicines

    Why we picked it: It is identified among major companies operating in global pain management markets through migraine medicines.

  3. Leader in therapeutic pain medicines

    AbbVie

    US

    Ranked #3 · 9.0 · Therapeutic pain medicines

    Why we picked it: It reports $3.769bn in 2025 therapeutic Botox revenue and $2.307bn from Ubrelvy and Qulipta.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the pain management industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Boston Scientific

Neuromodulation devices · US

9.3
2

Eli Lilly and Company

Migraine medicines · US

9.1
3

AbbVie

Therapeutic pain medicines · US

9.0
4

Medtronic

Neuromodulation devices · IE

8.9
5

Pfizer

Prescription and OTC analgesics · US

8.8
6

Novartis

Migraine prevention medicines · CH

8.6
7

Sanofi

OTC analgesics and pain medicines · FR

8.5
8

Stryker

Pain-management and recovery devices · US

8.4
9

Teva Pharmaceutical Industries

Generic and specialty pain medicines · IL

8.0
10

Biohaven

Migraine and neurologic pain medicines · US

8.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the pain management industry. In Pain Management Industry Statistics. Gitnux. https://gitnux.org/pain-management-industry-statistics/#top-companies

report visual · Breakdown

Global pain management market share by segment

Pharmaceuticals holds the largest share at 91.5%.

91.5%
Pharmaceuticals
8.4%
Devices
source-verifiedsec.gov

04 Statistics

Technology & AI

AI adoption signals are concentrated in documentation and daily workflow use. Ambient documentation consideration sits at 60.8%, while 51% report using AI platforms daily in clinical practice.

AI and automation in the pain management industry

  • 60.8% of surveyed pain physicians identified ambient documentation as an AI application they were considering adopting.[1]
  • 51% of surveyed pain physicians reported using AI platforms daily in clinical practice in the international IPSIS survey.[1]
  • 75% of surveyed pain physicians had personally used or interacted with AI tools in clinical practice in the international IPSIS survey.[1]
  • 90.4% of anesthesiologists working in perioperative and pain care agreed that dedicated AI training would encourage adoption in practice.[1]

05 Statistics

Market Intelligence

Provider capacity measurements show broad national coverage alongside a large services market. The U.S. pain management services market was estimated at $44.5 billion in 2024 and included 3,554 active providers as of November 21, 2026.

Market size and service revenue in the pain management industry

  • $44.5 billion was the estimated 2024 U.S. pain management services market; KPMG defines the category as pain management services delivered by providers, excluding its separate economic-burden estimate.[2]

Firm counts and size structure in the pain management industry

  • 3,554 active pain management providers were listed nationally in the United States on November 21, 2026, with providers mapped by primary CMS-listed specialty taxonomy.[3]
  • 1,588 pain management practices operated in the United States in 2023, based on practices whose physician mix identified them as pain management practices.[4]
  • 2,241 pain management physicians worked in U.S. pain management practices in 2023, using Medicare Data on Provider Practice and Specialty denominators.[4]

06 Statistics

Strategy & Growth

Private-equity ownership and add-on deal structure stand out. By 2023, 8.2% of U.S. pain-management physicians worked in private-equity-owned practices, and 31 of 36 deals since January 2024 were add-ons.

M&A and consolidation in the pain management industry

  • 12 pain-management deals were announced through September 2026 in the United States, including 10 involving private-equity-backed buyers.[5]
  • 8.2% of U.S. pain-management physicians worked in private-equity-owned practices in 2023, compared with 0.4% in 2013.[4]
  • 69 U.S. pain-management practices were acquired by private equity through 2023, equal to 4.3% of 1,588 practices.[4]
  • 31 of 36 U.S. pain-management deals announced since January 2024 were add-on acquisitions to existing platforms.[5]

07 Statistics

People & Workforce

Fellowship fill rates are high in the 2026 appointment year. Out of 378 offered positions, 362 were filled, yielding 84% filled positions.

Skills and certification in the pain management industry

  • 84% of U.S. Pain Medicine fellowship positions were filled in the 2026 appointment year, calculated from 362 filled positions out of 378 offered.[6]
  • 112 U.S. Pain Medicine fellowship programs participated in the 2026 appointment-year match, including 84 filled and 28 unfilled programs.[6]
  • 378 Pain Medicine fellowship positions were offered in the United States for the 2026 appointment year, with 362 filled and 16 unfilled.[6]

08 Statistics

Pricing

Medicare ASC payment levels vary by procedure codes used in ambulatory pain care. For 2026, CPT 64575 is paid at $5,184.89 and CPT 64483 at $392.62.

Fees and price levels in the pain management industry

  • $5,184.89 was the 2026 Medicare ASC payment amount for CPT 64575, implantation of neuroelectrodes; the study category is Medicare-covered pain procedures performed in ambulatory surgical centers.[7]
  • $392.62 was the 2026 Medicare ASC payment amount for CPT 64483, lumbar or sacral transforaminal epidural injection; the study category is Medicare-covered pain procedures performed in ambulatory surgical centers.[7]
  • $765.89 was the 2026 Medicare ASC payment amount for CPT 64600, injection treatment of a nerve; the study category is Medicare-covered pain procedures performed in ambulatory surgical centers.[7]

09 Statistics

Risk & Compliance

Compliance timelines and monitoring cadence drive operational risk controls. The HHS Part 2 Final Rule deadline for providers subject to the updated requirements is February 16, 2026.

Regulation and licensing in the pain management industry

  • February 16, 2026 was the compliance deadline under HHS’s 2024 Part 2 Final Rule for providers subject to the updated substance-use-disorder-record confidentiality requirements.[8]
  • Every 3 months is the CDC-recommended maximum interval for reviewing a state PDMP when continuing opioid therapy for acute, subacute or chronic pain.[9]
  • April 16, 2024 was the effective date of HHS’s 2024 Part 2 Final Rule, which updated confidentiality requirements for substance-use-disorder records relevant to pain practices treating such patients.[8]

Incidents, safety and loss events in the pain management industry

  • $451,000 was agreed in 2026 by Mission Advanced Pain Management & Spine Center and its physician to resolve allegations that claims exceeded allowed service limits.[10]
  • $1.5 million was agreed in November 2026 to resolve alleged medically unnecessary diagnostic-testing claims by two companies operating a Clarksville pain-management clinic and two managers.[10]
  • $427,129.11 was paid in May 2025 by Pain Management, LLC and its owner to resolve alleged false claims and Medicare overpayments.[10]
  • $13.625 million was paid in December 2025 to resolve alleged false claims involving urine drug testing by an Austin pain-management doctor and affiliated practices.[10]

Key questions about the pain management industry

What is the estimated global size of the pain management market in 2026?
The global pain management market is estimated at $80.93 billion in 2026.
How fast is the pain management market expected to grow after 2026?
The cited forecast grows the global pain management market at a 4.7% CAGR from 2026 onward.
Which companies lead the pain management industry?
Boston Scientific stands out for neuromodulation-focused chronic pain care because its Neuromodulation segment generated $1.199bn in 2025 including its Pain franchise, while Eli Lilly and Company focuses on migraine medicines since it is identified among the major companies operating in global pain management markets.
What technology shifts are showing up in pain care workflows?
Pain physicians report ambient documentation interest (60.8%) and daily use of AI platforms (51%) in the IPSIS survey, with 90.4% of anesthesiologists supporting dedicated AI training.
How is the U.S. pain management services market sized and structured by providers?
The U.S. pain management services market was estimated at $44.5 billion in 2024, and 3,554 active pain management providers were listed nationally on November 21, 2026.
What compliance and monitoring cadence matters for opioid continuation policies?
Every 3 months is the CDC-recommended maximum interval for reviewing a state PDMP when continuing opioid therapy for acute, subacute or chronic pain.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Pain Management Industry Statistics. Gitnux. https://gitnux.org/pain-management-industry-statistics
MLA
Samuel Norberg. "Pain Management Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/pain-management-industry-statistics.
Chicago
Samuel Norberg. 2026. "Pain Management Industry Statistics." Gitnux. https://gitnux.org/pain-management-industry-statistics.